Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02872025 · ClinicalTrials.gov registry record · Early Phase 1
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
A Early Phase 1 study of Carcinoma, Intraductal, Noninfiltrating, sponsored by Laura Esserman.
- Active
- Registry status
- Early Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT02872025 is a Early Phase 1 study of Carcinoma, Intraductal, Noninfiltrating that is active but no longer recruiting, run by Laura Esserman. The registered enrollment target is 42 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02872025, a Early Phase 1 study of Carcinoma, Intraductal, Noninfiltrating, is active but no longer recruiting, sponsored by Laura Esserman.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL Intralesional mRNA 2752
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-12-12 |
| Est. Completion | 2026-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02872025
The ClinicalTrials.gov registry entry for NCT02872025 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laura Esserman, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Intraductal, Noninfiltrating appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02872025 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02872025 about?
NCT02872025 is a clinical study titled "Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)". This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.
What is the current status of trial NCT02872025?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 42 participants. The study started on 2016-12-12. Estimated completion is 2026-03-31.
What conditions does trial NCT02872025 study?
This clinical trial studies the following conditions: Carcinoma, Intraductal, Noninfiltrating.
What interventions are being tested in trial NCT02872025?
The interventions under investigation include: Pembrolizumab (DRUG), Intralesional mRNA 2752 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02872025?
This trial is sponsored by Laura Esserman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02872025 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.